Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Other Non Operating Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Non Operating Income for 4 consecutive years, with $97000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 61.2% to $97000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $278000.0, a 18.8% increase, with the full-year FY2024 number at $354000.0, up 192.43% from a year prior.
  • Other Non Operating Income was $97000.0 for Q3 2025 at Century Therapeutics, down from $113000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $4.4 million in Q4 2022 to a low of -$194000.0 in Q1 2023.
  • A 4-year average of $462266.7 and a median of $97000.0 in 2025 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 1983.33% in 2024, then tumbled 445.45% in 2025.
  • Century Therapeutics' Other Non Operating Income stood at $4.4 million in 2022, then tumbled by 100.34% to -$15000.0 in 2023, then soared by 806.67% to $106000.0 in 2024, then dropped by 8.49% to $97000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Other Non Operating Income are $97000.0 (Q3 2025), $113000.0 (Q2 2025), and -$38000.0 (Q1 2025).